Rockefeller Capital Management L.P. Crispr Therapeutics Ag Transaction History
Rockefeller Capital Management L.P.
- $42.4 Billion
- Q2 2025
A detailed history of Rockefeller Capital Management L.P. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 115,356 shares of CRSP stock, worth $7.88 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
115,356
Previous 115,356
-0.0%
Holding current value
$7.88 Million
Previous $5.61 Million
-0.0%
% of portfolio
0.01%
Previous 0.02%
Shares
25 transactions
Others Institutions Holding CRSP
# of Institutions
535Shares Held
68.7MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$695 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$382 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$252 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$223 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$194 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.33B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....